Emerging research suggest Retatrutide , a dual activator targeting both incretin and another hormone, could offer a significant advancement for body management . Preliminary human trials have demonstrated considerable reductions in body tissue, potentially exceeding existing body composition medications . Nevertheless , further assessment is necess